Elamipretide protects mouse ovaries from cisplatin damage via Nrf2/HO-1

The wire

1. 01Researchers induced premature ovarian failure with intraperitoneal cisplatin 2 mg/kg for seven days, then treated mice with the mitochondria-targeted peptide SS-31 at 10 mg/kg for three weeks.
2. 02SS-31 treatment improved ovarian size and morphology, raised follicle counts, reduced oxidative stress and activated Nrf2/HO-1 signaling in ovarian tissue, per the Frontiers in Pharmacology report.
3. 03This is a mouse model only; the authors call SS-31 a candidate for clinical management of premature ovarian failure, but no human data in this indication are presented.

From the source

Mitochondria-targeted peptide elamipretide alleviates cisplatin-induced ovarian failure by activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway

Frontiers in pharmacology · 2026 · Zhao Y, Yan H, Wang L et al.